CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Crispr Therapeutics AG has experienced a notable decline in its stock price over the past week, dropping by 8.60%. This downturn comes despite several positive analyst ratings and price target ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.59%. On the other hand, the ...

Crispr Therapeutics CRSP is having quite a year: The pure-play gene editing company’s stock is up 65% year to date through Sept. 30. Yet even after its runup, this top-performing stock is trading 40% ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a ...